- On Thursday, pharma giant Eli Lilly and Co. announced positive results in a mid-stage trial for its experimental new diabetes drug. The company’s stock rose 3% on the news.
- The drug significantly reduced blood sugar levels and promoted weight loss in patients with type 2 diabetes.
- The late-stage trial for this drug is expected to be completed in 2021.
- This drug has to potential to boost Lilly’s growing portfolio of drugs extending across the areas of oncology, cardiovascular, diabetes, critical care, neuroscience, men’s health and musculoskeletal fields.
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.